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Abstract 
Short communication on t(9;9)(p13;p24) 
PAX5/JAK2, with data on clinics, and the genes 
implicated. 
Clinics and pathology 
Disease 
B-cell acute lymphoblastic leukemia (B-ALL) 
Phenotype/cell stem origin 
Three cases were CD10+, and one case was Cµ. 
Embryonic origin 
Only four cases to date (Nebral et al., 2009; Coyaud 
et al., 2010; Roberts et al., 2012). 
Epidemiology 
This chromosome abnormality has only been found 
so far in childhood B-ALL: there were 2 male and 2 
female patients, aged 7, 10, 13 and 14 years. 
Prognosis 
Two of three patients were considered as being at 
high risk, and one at intermediate risk.  
One patient was in complete remission (CR) 65 
months after diagnosis, and another one was in a 
second CR at 10 months+ (Nebral et al., 2009). 
 
 
Cytogenetics 
Cytogenetics morphological 
Additional chromosome abnormalities were noted 
in the two cases with complete data on the 
karyotypes. 
Genes involved and 
proteins 
JAK2 
Location 
9p24.1 
Protein 
1132 amino acids (aa); from N-term to C-term, 
JAK2 contains: an interaction region with 
cytokine/interferon/growth hormone receptors: aa 
1-239, a FERM domain: aa 37-380, a SH2 domain: 
aa 401-482, two protein kinase domains: aa 545-
809 and 849-1124, an ATP nucleotide binding site: 
aa 855-863, and a loop structure: aa 1056-1078 
(JAK2 kinase insertion loop).  
JAK homology domains are the following: JH7: aa 
25-137; JH6: aa 144-284; JH5: aa 288-309; JH4: aa 
322-440; JH3: aa 451-538; JH2: aa 543-824; JH1: 
836-1123.  
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PAX5/JAK2 fusion protein. 
 
Phosphotyrosines are located at aa 119, 372, 373, 
523, 813, 868, 966, 972, 1007, and 1008 (Harpur et 
al., 1992; Saltzman et al., 1998; Lucet et al., 2006). 
Protein tyrosine kinase of the non-receptor type that 
associates with the intracellular domains of 
cytokine receptors; Mediates signaling 
transduction. 
PAX5 
Location 
9p13.2 
Protein 
391 amino acids; from N-term to C-term, PAX5 
contains: a paired domain (aa: 16-142); an 
octapeptide (aa: 179-186); a partial homeodomain 
(aa: 228-254); a transactivation domain (aa: 304-
359); and an inhibitory domain (aa: 359-391). 
Lineage-specific transcription factor; recognizes the 
concensus recognition sequence 
GNCCANTGAAGCGTGAC, where N is any 
nucleotide.  
Involved in B-cell differentiation. Entry of common 
lymphoid progenitors into the B cell lineage 
depends on E2A, EBF1, and PAX5; activates B-cell 
specific genes and repress genes involved in other 
lineage commitments.  
Activates the surface cell receptor CD19 and 
repress FLT3.  
Pax5 physically interacts with the RAG1/RAG2 
complex, and removes the inhibitory signal of the 
lysine-9-methylated histone H3, and induces V-to-
DJ rearrangements.  
Genes repressed by PAX5 expression in early B 
cells are restored in their function in mature B cells 
and plasma cells, and PAX5 repressed (Fuxa et al., 
2004; Johnson et al., 2004; Zhang et al., 2006; 
Cobaleda et al., 2007; Medvedovic et al., 2011). 
Result of the chromosomal 
anomaly 
Hybrid gene 
Description 
Fusion of PAX5 exon 5 to JAK2 exon 19 in each 
case. Opposite direction is noted by Coyaud et al., 
2010. 
Fusion protein 
Description 
522 amino acids (201 from PAX5 and 321 from 
JAK2).  
The predicted fusion protein contains the DNA 
binding paired domain of PAX5 and the Protein 
kinase 2 domain from JAK2 (breakpoint at aa 811 
or 812 in JAK2). 
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